What should be done when serial carbohydrate antigen 19‑9 (CA 19‑9) tumor marker levels continue to rise?

Rising CA 19-9 Levels: Clinical Action Plan

When serial CA 19-9 levels continue to rise, you must immediately confirm with imaging studies (CT or MRI) and/or tissue biopsy to determine if this represents progressive disease, as CA 19-9 elevation alone cannot definitively establish disease progression or recurrence. 1

Clinical Context Determines Next Steps

The interpretation and management of rising CA 19-9 depends critically on the patient's current disease status:

In Patients on Active Treatment for Advanced/Metastatic Disease

• Rising CA 19-9 during chemotherapy suggests treatment failure and should prompt consideration of changing the chemotherapy regimen 1
• However, you cannot make treatment decisions based on CA 19-9 alone—obtain confirmatory imaging (multiphasic CT or MRI) to document actual disease progression 2
• Monitor CA 19-9 every 1-3 months during active treatment 1
• Key caveat: Falling CA 19-9 correlates with improved survival and treatment response, while rising levels correlate with shorter survival times 1

In Post-Surgical Patients (Surveillance Setting)

• Rising CA 19-9 after resection may indicate recurrence but requires confirmation with imaging and/or biopsy before declaring recurrence 1
• This applies whether the patient is receiving adjuvant therapy or under observation
• Do not restart treatment or change management based solely on tumor marker elevation

In Patients Being Considered for Surgery After Neoadjuvant Therapy

• Post-induction CA 19-9 >200 U/mL identifies patients with very poor prognosis who should not undergo radical surgery (2-year survival only 41.4%) 3
• The best surgical outcomes occur with:
  • Post-induction CA 19-9 <50 U/mL

  • 80% decrease from baseline CA 19-9

  • Performance status of 0 4
• Critical point: Baseline CA 19-9 is NOT prognostic after surgical exploration—only the post-treatment level and degree of decrease matter 4

Essential Diagnostic Work-Up for Rising CA 19-9

When you detect rising CA 19-9, systematically evaluate for:

1. Malignant causes (most important):

   • Multiphasic contrast-enhanced CT (thoracic-abdominal-pelvic) with late arterial and portal venous phases 2
   • Consider PET-CT if distant metastases are uncertain or imaging is equivocal 2
   • Hepatic MRI before any surgical decision to exclude small liver metastases 2

2. Benign causes that can elevate CA 19-9:

   • Hepatobiliary disease: Biliary obstruction (benign or malignant), cholangitis, cirrhosis 1, 5, 6
   • Pulmonary disease: Pneumonia, pleural effusion 5, 6
   • Gynecologic disease: Ovarian pathology 5
   • Endocrine disease: Diabetes mellitus, thyroid disease 1, 7
   • Renal failure 6
   • Autoimmune conditions: SLE 6

3. Technical considerations:

   • Confirm the patient is not Lewis antigen-negative (5% of population cannot produce CA 19-9) 1
   • Repeat the test to verify the elevation is real

Monitoring Strategy Based on Trend

If CA 19-9 shows an increasing trend:

• Monitor at 1,3, and 6-month intervals until malignancy is excluded 8
• Obtain confirmatory imaging at each interval showing increase
• Consider tissue diagnosis if imaging shows suspicious findings

If CA 19-9 decreases or normalizes:

• Monitor annually 8
• Less aggressive surveillance is appropriate

Critical Pitfalls to Avoid

1. Never use CA 19-9 alone to make treatment decisions—it has insufficient specificity even when rising 1

2. Do not assume rising CA 19-9 always means cancer progression—benign conditions account for approximately 27-37% of elevated CA 19-9 cases in follow-up studies 5, 8

3. In asymptomatic patients with elevated CA 19-9 but no known cancer, the positive predictive value for pancreatic cancer is only 0.9% despite high sensitivity 9. Systematic evaluation is needed, but avoid over-investigation

4. Preoperative CA 19-9 >500 U/mL suggests worse prognosis but should not alone determine operability—use in conjunction with imaging findings 2

5. Rising CA 19-9 has different implications at different disease stages—context is everything. A rise from 50 to 100 U/mL in surveillance is different from a rise from 1000 to 2000 U/mL on chemotherapy

The Bottom Line

The 2023 ESMO pancreatic cancer guidelines emphasize that CA 19-9 is a prognostic factor in advanced disease but must be interpreted alongside imaging 2. The consistent message across all ASCO guidelines is that CA 19-9 determinations by themselves cannot provide definitive evidence and require confirmation with imaging or biopsy 1. Rising CA 19-9 is a red flag that demands investigation, not a diagnosis in itself.